NODAGA-LM3 TFA
NODAGA-LM3 TFA is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC50 = 1.3 nM). NODAGA-LM3 TFA does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 TFA shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. 68Ga-labeled NODAGA-LM3 TFA can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors.
For research use only. We do not sell to patients.
- Formula: C70H91ClF3N15O21S2.xC2HF3O2
- Molecular Weight:1521.11 (free acid)
-
Storage:
Sealed storage, away from moisture and light.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Radionuclide-Drug Conjugates (RDCs) Isoforms
More
Biological Activity
|
SSTR2 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Appearance Solid
-
Molecular Weight 1521.11 (free acid)
-
Formula C70H91ClF3N15O21S2.xC2HF3O2
-
Color White to off-white
-
Sequence
{NODAGA}-{p-Cl-Phe}-{d-Cys}-Tyr-{d-Phe(4-amino-carbamoyl)}-Lys-Thr-Cys-{d-Tyr}-NH2 (Disulfide bridge: Cys2-Cys7)
-
Sequence Shortening
{NODAGA}-{p-Cl-Phe}-{d-Cys}-Y-{d-Phe(4-amino-carbamoyl)}-KTC-{d-Tyr}-NH2 (Disulfide bridge: Cys2-Cys7)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture and light
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Liu M, et al. Staging, heterogeneity analysis and early treatment response evaluation based on 68Ga-NODAGA-LM3 and 18F-FDG PET/CT in small cell lung cancer patients[J]. 2025. [Content Brief]
[2]. Zhu W, et al. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE[J]. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49(5): 1613-1622. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NODAGA-LM3 TFA Related Classifications
HY-P5362A Related Classifications
Powered by Bioz